TLR4 and Sepsis: Thus, two TLR4 antagonists TAK-242 and Eritoran reached clinical trials as anti-sepsis agents, unfortunately both failed to suppress cytokine levels or improve the survival of septic patients (Rice et al., 2010; Anwar et al., 2019).